The Center for Hematologic Oncology provides outstanding care for patients with all types of hematologic malignancies and aims to advance the field through innovative clinical and basic research. In addition, the center provides unique educational opportunities for physicians, medical students, postdoctoral fellows, and other health care professionals. The center is comprised of faculty involved in clinical research, clinical care, and basic laboratory studies and is informally subdivided into five programs: Leukemia, Lymphoma, Multiple Myeloma, Stem Cell/Bone Marrow Transplant/Immunotherapy, and Waldenström's Macroglobulinemia.

The division is made up of the five specific programs listed below.

• Leukemia

  The Adult Leukemia Program provides comprehensive, high-quality care to patients with leukemia and similar bone-marrow disorders. Through an active program of clinical research, the program also strives to rapidly translate advances in the understanding of leukemia and related disorders into therapies that will benefit patients today and in the future.

• Lymphoma

  The Lymphoma Program provides comprehensive, state-of-the-art care for patients with lymphoid malignancies. Each patient's care combines the best treatments currently available for specific lymphoid tumors with innovative new therapies based on research under way in the program's laboratories and elsewhere.

• Multiple Myeloma

  The Jerome Lipper Multiple Myeloma Center provides comprehensive, state-of-the-art care, including promising new therapies through clinical trials, to patients with multiple myeloma. In addition, the center conducts an active program of basic and clinical research aimed at improving the outcomes of patients with multiple myeloma.

• Stem Cell/Bone Marrow Transplantation

  Established in the early 1970s, the Hematopoetic Stem Cell Transplantation (HSCT) Program was one of the first such programs in the world, and is now one of the largest and busiest in the United States. Since its inception, the Program has performed more than 5,000 transplants, and now performs more than 370 transplants each year.

• Waldenström's Macroglobulinemia

  The Bing Center for Waldenström's macroglobulinemia provides comprehensive care, including promising new therapies through clinical trials, to patients with Waldenström's macroglobulinemia and related IgM disorders.

See a selection of clinical trials for hematologic malignancies (PDF)